MedPath

Boehringer Ingelheim USA Corporation

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Bioequivalence Study of Telmisartan/Amlodipine Fixed Dose Combination Compared With Its Monocomponents in Healthy Male and Female Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Telmisartan/Amlodipine
First Posted Date
2014-10-09
Last Posted Date
2014-10-09
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
84
Registration Number
NCT02259829

Study to Determine Pharmacodynamic Effects and Pharmacokinetics of KUC 7483 CL in Patients With Spinal Cord Injury and Neurogenic Detrusor Overactivity

Phase 1
Completed
Conditions
Spinal Cord Injuries
Interventions
Drug: Placebo
Drug: KUC 7483 CL
First Posted Date
2014-10-09
Last Posted Date
2014-10-09
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
26
Registration Number
NCT02259751

Study to Investigate the Regional Drug Absorption of KUC-7483 CL Administered Via an Enterion™ Capsule Compared to an Immediate Release Formulation in Healthy Male Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: KUC 7483 CL, immediate release tablet
Drug: KUC 7483 CL, particulate formulation
Drug: KUC 7483 CL, solution formulation
Device: Enterion™ capsule
First Posted Date
2014-10-09
Last Posted Date
2014-10-09
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
13
Registration Number
NCT02259920

Telmisartan in Mild to Moderate Hypertensive Patients

Phase 4
Completed
Conditions
Hypertension
Interventions
Drug: Low dose of telmisartan
Drug: High dose of telmisartan
Drug: Placebo
First Posted Date
2014-10-09
Last Posted Date
2014-10-09
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
134
Registration Number
NCT02260089

Safety, Pharmacokinetics, and Pharmacodynamics of BIRT 2584 XX in Healthy Male Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
First Posted Date
2014-10-09
Last Posted Date
2014-10-09
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
55
Registration Number
NCT02259894

Safety, Tolerability and Pharmacokinetics of BI 34021 FU2 Oral Drinking Solution in Healthy Male Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BI 34021 FU2 solution
Drug: Placebo
Drug: BI 34021 FU2 tablet
Other: High fat, high calorie breakfast
First Posted Date
2014-10-09
Last Posted Date
2014-10-09
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
63
Registration Number
NCT02259842

Bioavailability of Telmisartan/Amlodipine Fixed-dose Combination Compared to Its Mono-components in Healthy Male Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Telmisartan/amlodipine fixed-dose combination tablet
First Posted Date
2014-10-09
Last Posted Date
2014-10-09
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
30
Registration Number
NCT02259790

Metabolism and Pharmacokinetics of [14C] BEA 2180 BR Administered Orally Compared to [14C] BEA 2180 BR Administered Intravenously in Healthy Male Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BEA 2180 BR infusion
Drug: BEA 2180 BR oral
First Posted Date
2014-10-08
Last Posted Date
2014-10-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
14
Registration Number
NCT02258971

Safety, Tolerance, and Pharmacokinetics of Single Rising Oral Doses of BILB 1941 ZW Solution in Healthy Male Subjects, Followed With Bioavailability Comparison of BILB 1941 ZW Tablet and Solution Formulation Administered With or Without Food

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BILB 1941 ZW - single rising dose part
Drug: Placebo
Drug: BILB 1941 ZW - tablet
Drug: BILB 1941 ZW - solution
Other: standardized breakfast
First Posted Date
2014-10-06
Last Posted Date
2014-10-06
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
56
Registration Number
NCT02256787

Safety, Tolerability and Pharmacokinetics of Oral BIBP 5371 CL in Healthy Male and Female Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BIBP 5371 CL tablet low dose
Drug: BIBP 5371 CL tablet high dose
Drug: Placebo drinking solution
Drug: BIBP 5371 CL solution
Other: High fat, high caloric breakfast
Drug: BIBP 5371 CL tablet
Drug: Placebo tablet
First Posted Date
2014-10-06
Last Posted Date
2014-10-06
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
70
Registration Number
NCT02256709
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy